TL;DR

At CES 2026, health tech startup Vivoo introduced the FlowPad, a menstrual pad that doubles as an at-home hormone test. The disposable product is reported to detect follicle-stimulating hormone (FSH) and is priced at roughly $4 to $5 per pad.

What happened

At the Consumer Electronics Show 2026, Vivoo, a health technology startup, revealed the FlowPad: a menstrual pad designed to function as an at-home hormone test. According to the announcement, the FlowPad measures follicle-stimulating hormone (FSH) from menstrual blood and is priced at approximately $4 to $5 per pad. Vivoo presented the product amid a broader industry push to monitor a variety of bodily fluids—blood, urine, sweat and saliva—and the FlowPad signals the addition of menstrual blood to that list. The available information is limited to the CES reveal and basic product claims; many operational details such as how results are reported, accuracy, or whether the pad connects to an app were not provided in the source. Vivoo framed the FlowPad as part of its consumer-facing health offerings, but distribution timing and regulatory status were not detailed in the announcement.

Why it matters

  • Expands at-home testing to menstrual blood, broadening the range of bodily fluids used for consumer health monitoring.
  • FSH is a key reproductive hormone; an accessible test could change how people track aspects of fertility and hormonal health.
  • Low per-unit pricing could make hormone checks more frequent and affordable if accuracy and access are validated.
  • Raises questions about data handling, clinical validation and regulatory oversight for new forms of consumer diagnostics.

Key facts

  • Product name: FlowPad (announced by Vivoo at CES 2026).
  • Measures follicle-stimulating hormone (FSH) from menstrual blood.
  • Reported price is roughly $4 to $5 per pad.
  • Positioned amid a trend of companies developing diagnostics from bodily fluids such as blood, urine, sweat and saliva.
  • Manufacturer: Vivoo, a health tech startup.
  • Availability or retail rollout: not confirmed in the source.
  • Accuracy, sensitivity and clinical validation data: not confirmed in the source.
  • Whether the product requires a smartphone app, reader or provides digital results: not confirmed in the source.

What to watch next

  • Regulatory clearance and clinical validation studies to verify test accuracy and safety: not confirmed in the source.
  • Details on how users receive and interpret results (paper readout, app, or third-party analysis): not confirmed in the source.
  • Market availability and distribution plans following the CES reveal: not confirmed in the source.

Quick glossary

  • Follicle-stimulating hormone (FSH): A hormone involved in reproductive processes; commonly measured in evaluations of fertility and endocrine function.
  • At‑home test: A diagnostic test designed to be used by consumers outside a clinical setting, often for screening or monitoring health conditions.
  • Menstrual blood: Blood and tissue shed from the lining of the uterus during menstruation; it can contain biochemical markers used in some health tests.
  • CES (Consumer Electronics Show): An annual trade show where companies often unveil new consumer electronics and technology products.

Reader FAQ

What hormone does the FlowPad test detect?
The FlowPad is reported to measure follicle-stimulating hormone (FSH).

How much does a FlowPad cost?
The product is said to be roughly $4 to $5 per pad.

When and where will FlowPad be available to buy?
Not confirmed in the source.

How accurate is the FlowPad compared with lab tests?
Not confirmed in the source.

The FlowPad will measure follicle-stimulating hormone. | Image: Vivoo Wellness tech companies are increasingly interested in bodily fluids like blood, urine, sweat, and saliva. At CES 2026, it's time to…

Sources

Related posts

By

Leave a Reply

Your email address will not be published. Required fields are marked *